Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        1-12 of 18 results

        Refine research

        Research

        OPTIMUM: OPTimising IMmunisation Using Mixed schedules

        Pat Peter Susan Tom Jennifer Holt Richmond Prescott Snelling Kent PG PC SL T J PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP MBBS BMedSci PhD FRACP BMBS DTMH GDipClinEpid PhD FRACP RN Emeritus Honorary Researcher Head, Vaccine Trials Group ...

        Research

        A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in children

        Chris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton C J LK PC RT PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear Health Clinical Research Manager Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, ...

        Research

        COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years o

        Peter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group which sits in the Wesfarmers Centre of Vaccines and Infectious Diseases. Professor Richmond is a ...

        Research

        A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine: A phase 2prospective randomised open-label feasibility study (FluBub)

        Christopher Peter Blyth Richmond CC PC MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP Director, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious ...

        Research

        Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 years

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        A phase 3, randomized, double-blinded, placebo-controlled trial toevaluate the efficacy and safety of a respiratory syncytial virus (RSV) prefusion F subunit vaccine in infants born to women vaccinated during pregnancy (Matisse)

        Peter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group which sits in the Wesfarmers Centre of Vaccines and Infectious Diseases. Professor Richmond is a ...

        Research

        A Phase I/II, Multicentre, Observer-blinded, Randomized, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) in Compari

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Research

        BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial

        Jennifer Peter Kent Richmond J PC RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at ...

        Page 1 of 2